Our Services
Building successful market access strategies for novel pharmaceuticals is fundamentally an exercise in understanding trade-offs between positioning and price. ValueRx works with organisations to help them make the best-informed decisions by better understanding the landscape and strategic context for their unique situations, through a combination of focused research and expert opinions
I. Treatment pathway analysis
How are patients treated?
Key Topics Covered:
- Patient journey and funnel
- Treatment paradigm and utilisation patterns
- Key uptake decision-drivers/ barriers
II. Payer value driver assessment
How will payers determine value?
Key Topics Covered:
- Buyer landscape and access stakeholder mapping
- Competitor landscape and dynamics
- Payer value drivers and benchmarks
- Payer and Health Technology Assessment (HTA) learnings
II. Payer value driver assessment
How will payers determine value?
Key Topics Covered:
- Buyer landscape and access stakeholder mapping
- Competitor landscape and dynamics
- Payer value drivers and benchmarks
- Payer and Health Technology Assessment (HTA) learnings
III. Value proposition and pricing
What are the payer strategy options and implications?
Key Topics Covered:
- Therapeutic positioning options
- Pricing scenarios and strategies
- Evidence requirements and trial design
- Gap analysis
IV. Innovative access models
What additional strategies are required to deliver access and price?
Key Topics Covered:
- Managed entry agreement/ risk sharing models
- Indication-based pricing assessment
- Early access/ compassionate use programs
- Value-based care/ beyond-the-product solutions
IV. Innovative access models
What additional strategies are required to deliver access and price?
Key Topics Covered:
- Managed entry agreement/ risk sharing models
- Indication-based pricing assessment
- Early access/ compassionate use programs
- Value-based care/ beyond-the-product solutions
V. Price monitoring and management
How will price be impacted?
Key Topics Covered:
- Price evolution assessment
- Future indication launch impact
- Competitor pricing risks and mitigation planning